* This study is no longer looking for participants *

The AuToDeCRA-2 study was designed to investigate the best route of delivery for a new investigative treatment for Rheumatoid Arthritis called TolDC. TolDC is a new medicine that is developed from a person's own white blood cells.

All participants in the study have completed their study visits and the team are now working on analysing the tissue samples and data collected during the study.  This is expected to take up to a year and we look forward to sharing the results of the study with everybody in 2026.

The main criteria to take part was that participants had to be an adult (aged 18 or over), have had a diagnosis of Rheumatoid Arthritis (RA) for at least 4 months but less than 10 years, and be on stable medication for their RA.

The study is took place at The Newcastle upon Tyne Hospitals NHS Foundation Trust.

‎